دورية أكاديمية
أعرض في EDS

Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.

التفاصيل البيبلوغرافية
العنوان: Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology.
المؤلفون: O'Meara CP; Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, Queensland, Australia., Armitage CW, Harvie MC, Timms P, Lycke NY, Beagley KW
المصدر: PloS one [PLoS One] 2013 Apr 16; Vol. 8 (4), pp. e61962. Date of Electronic Publication: 2013 Apr 16 (Print Publication: 2013).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Chlamydia/*immunology , Chlamydia/*pathogenicity , Chlamydia Infections/*immunology , Chlamydia Infections/*prevention & control , Vaccination/*methods, Animals ; Interferon-gamma/metabolism ; Interleukin-17/metabolism ; Mice ; Tumor Necrosis Factor-alpha/metabolism
مستخلص: Chlamydia pneumoniae is responsible for up to 20% of community acquired pneumonia and can exacerbate chronic inflammatory diseases. As the majority of infections are either mild or asymptomatic, a vaccine is recognized to have the greatest potential to reduce infection and disease prevalence. Using the C. muridarum mouse model of infection, we immunized animals via the intranasal (IN), sublingual (SL) or transcutaneous (TC) routes, with recombinant chlamydial major outer membrane protein (MOMP) combined with adjuvants CTA1-DD or a combination of cholera toxin/CpG-oligodeoxynucleotide (CT/CpG). Vaccinated animals were challenged IN with C. muridarum and protection against infection and pathology was assessed. SL and TC immunization with MOMP and CT/CpG was the most protective, significantly reducing chlamydial burden in the lungs and preventing weight loss, which was similar to the protection induced by a previous live infection. Unlike a previous infection however, these vaccinations also provided almost complete protection against fibrotic scarring in the lungs. Protection against infection was associated with antigen-specific production of IFNγ, TNFα and IL-17 by splenocytes, however, protection against both infection and pathology required the induction of a similar pro-inflammatory response in the respiratory tract draining lymph nodes. Interestingly, we also identified two contrasting vaccinations capable of preventing infection or pathology individually. Animals IN immunized with MOMP and either adjuvant were protected from infection, but not the pathology. Conversely, animals TC immunized with MOMP and CTA1-DD were protected from pathology, even though the chlamydial burden in this group was equivalent to the unimmunized controls. This suggests that the development of pathology following an IN infection of vaccinated animals was independent of bacterial load and may have been driven instead by the adaptive immune response generated following immunization. This identifies a disconnection between the control of infection and the development of pathology, which may influence the design of future vaccines.
References: J Immunol. 2002 Nov 1;169(9):5236-43. (PMID: 12391242)
J Immunol. 1997 Apr 15;158(8):3936-46. (PMID: 9103464)
Clin Exp Allergy. 2009 Dec;39(12):1910-9. (PMID: 19694757)
PLoS One. 2012;7(3):e33781. (PMID: 22438999)
Reg Immunol. 1993 Nov-Dec;5(6):317-24. (PMID: 8068534)
Am J Trop Med Hyg. 2001 Nov;65(5):420-6. (PMID: 11716093)
Infect Immun. 1995 Jul;63(7):2801-3. (PMID: 7790105)
J Immunol. 2004 Jul 15;173(2):1209-18. (PMID: 15240712)
Infect Immun. 1997 Jul;65(7):2876-82. (PMID: 9199462)
Vaccine. 2009 Aug 6;27(36):5020-5. (PMID: 19446590)
Infect Immun. 2007 Jan;75(1):408-16. (PMID: 17074845)
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18406-11. (PMID: 22042859)
J Interferon Cytokine Res. 2003 Aug;23(8):413-21. (PMID: 13678429)
J Immunol. 2009 Dec 1;183(11):6933-8. (PMID: 19890060)
J Immunol. 1999 Mar 15;162(6):3541-8. (PMID: 10092812)
J Orthop Res. 2011 Jan;29(1):1-7. (PMID: 20665551)
Am J Reprod Immunol. 2011 Feb;65(2):118-26. (PMID: 20618179)
Parasite Immunol. 2001 Aug;23(8):435-44. (PMID: 11489167)
Infect Immun. 2004 Feb;72(2):1019-28. (PMID: 14742549)
Mech Ageing Dev. 2004 Dec;125(12):889-98. (PMID: 15563935)
J Immunol. 2004 Sep 1;173(5):3310-9. (PMID: 15322194)
Infect Immun. 2010 May;78(5):2272-82. (PMID: 20231405)
Am J Trop Med Hyg. 2001 Aug;65(2):159-61. (PMID: 11508393)
Indian J Med Res. 2011 Feb;133:153-63. (PMID: 21415489)
Infect Immun. 1981 Mar;31(3):1161-76. (PMID: 7228399)
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1607-12. (PMID: 22160692)
Scand J Immunol. 2006 Feb;63(2):97-105. (PMID: 16476008)
J Immunol. 2009 Nov 1;183(9):5886-95. (PMID: 19812198)
J Infect Dis. 1992 Sep;166(3):646-9. (PMID: 1500751)
J Immunol. 1998 Aug 1;161(3):1439-46. (PMID: 9686609)
Infect Immun. 2007 Mar;75(3):1359-63. (PMID: 17220311)
Infect Immun. 2008 Dec;76(12):5581-7. (PMID: 18809664)
Vaccine. 2006 Jan 16;24(3):355-66. (PMID: 16153755)
J Control Release. 2009 Sep 1;138(2):134-40. (PMID: 19426770)
Vaccine. 2002 Mar 15;20(13-14):1733-40. (PMID: 11906760)
J Immunol. 2011 Oct 1;187(7):3641-52. (PMID: 21880985)
Infect Immun. 1999 Apr;67(4):1763-9. (PMID: 10085016)
Curr Top Microbiol Immunol. 2012;354:1-18. (PMID: 21053117)
J Immunol. 1999 Feb 15;162(4):2432-40. (PMID: 9973526)
Vaccine. 2012 Jan 5;30(2):475-85. (PMID: 22079265)
J Immunol. 1999 Jan 15;162(2):1010-7. (PMID: 9916727)
J Reprod Immunol. 2009 Jul;81(1):34-8. (PMID: 19501917)
FEMS Immunol Med Microbiol. 2012 Mar;64(2):265-72. (PMID: 22066647)
Immunity. 1998 Mar;8(3):275-83. (PMID: 9529145)
Protein Sci. 2001 Mar;10(3):622-30. (PMID: 11344330)
J Immunol. 1996 Jun 1;156(11):4338-44. (PMID: 8666805)
Immunology. 1999 Dec;98(4):510-9. (PMID: 10594682)
J Leukoc Biol. 1996 May;59(5):656-62. (PMID: 8656050)
Curr Top Microbiol Immunol. 2006;311:17-58. (PMID: 17048704)
J Immunol. 2008 Mar 15;180(6):4148-55. (PMID: 18322226)
Biol Reprod. 1999 Feb;60(2):508-14. (PMID: 9916021)
J Exp Med. 2003 Jan 20;197(2):153-62. (PMID: 12538655)
J Gen Virol. 2008 Dec;89(Pt 12):2954-2964. (PMID: 19008380)
Cytokine Growth Factor Rev. 2003 Dec;14(6):537-50. (PMID: 14563355)
Curr Mol Med. 2005 Sep;5(6):599-605. (PMID: 16178770)
Immunity. 1998 Jan;8(1):89-95. (PMID: 9462514)
Vaccine. 2007 Aug 14;25(33):6224-31. (PMID: 17629371)
Vaccine. 2002 Aug 19;20(25-26):3209-20. (PMID: 12163273)
Vaccine. 2007 Dec 12;25(51):8598-610. (PMID: 17996991)
Vaccine. 2006 Jan 30;24(5):544-51. (PMID: 16169634)
Infect Immun. 1998 Nov;66(11):5113-8. (PMID: 9784511)
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11143-8. (PMID: 8855323)
N Engl J Med. 2004 Feb 26;350(9):896-903. (PMID: 14985487)
J Investig Allergol Clin Immunol. 2002;12(2):73-9. (PMID: 12371533)
J Infect Dis. 1993 Apr;167(4):841-9. (PMID: 8450249)
Immunology. 2002 Feb;105(2):213-21. (PMID: 11872097)
J Med Microbiol. 2010 Nov;59(Pt 11):1267-1274. (PMID: 20724512)
J Infect Dis. 2000 Jun;181 Suppl 3:S402-10. (PMID: 10839724)
Clin Infect Dis. 1992 Jan;14(1):178-82. (PMID: 1571425)
Vaccine. 2009 Oct 19;27(44):6217-25. (PMID: 19698810)
Immunol Rev. 1999 Aug;170:197-222. (PMID: 10566152)
Trends Immunol. 2004 Jul;25(7):381-6. (PMID: 15207506)
Lancet. 2008 Jun 14;371(9629):2019-25. (PMID: 18554712)
Cell Immunol. 2004 Jul;230(1):56-64. (PMID: 15541719)
المشرفين على المادة: 0 (Interleukin-17)
0 (Tumor Necrosis Factor-alpha)
82115-62-6 (Interferon-gamma)
تواريخ الأحداث: Date Created: 20130425 Date Completed: 20131114 Latest Revision: 20211021
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC3628704
DOI: 10.1371/journal.pone.0061962
PMID: 23613984
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0061962